Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce
05 August 2010 - 10:00PM
Marketwired
Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company
specializing in the marketing and distribution of both prescription
and non-prescription medical products, is pleased to announce they
have signed an exclusive license agreement to market and distribute
a high potency, highly concentrated vitamin D-3 capsule. This
vitamin can be taken once a week in adjunct with calcium to help
reduce bone loss and joint pain.
Axxess Pharma's license agreement will allow the Company the
right to market the vitamin under their brand name in Canada and
select countries worldwide. The vitamin is currently being sold in
the United States.
Vitamin D deficiency has been known to contribute to
musculoskeletal symptoms and bone loss in women with breast cancer.
The high potency, once a week capsule will help reduce these costly
and painful symptoms while allowing patients and individuals the
ability to focus on their daily life. This capsule will also help
reduce fatigue, stiffness, joint pain and impaired muscle strength
associated when individuals take aromatase inhibitors.
"Vitamin D deficiency is a growing problem for the aging
population and children around the world. In today's fast paced
environment, individuals are finding it difficult to take vitamins
7 days a week. Our once a week, high potency Vitamin D-3 capsule
will solve this problem and help reduce bone loss and joint pain.
Based on the current demand, we anticipate accelerated revenue
growth from this product through 2011," stated Gerald Sequeira,
President/CEO.
For more information, please contact Investor Relations at (973)
351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that
focuses on the marketing of dermatological, therapeutic
nutritionals, pain management and diagnostic products in Canada and
abroad since 1997. Axxess owns 22 established pharmaceutical
prescription products that have proven sales in Canada and
internationally. The company has an experienced management team and
field sales force to market products nationally to hospitals and
retail pharmacies as well as specialized practice areas including
Dermatology and Nephrology, Neurology and Urology.
Safe Harbor
Statements about the Company's future expectations and all other
statements in this press release other than historical facts are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created
thereby.
The above information contains information relating to the
Company that is based on the beliefs of the Company and/or its
management, as well as assumptions made by any information
currently available to the Company or its management. When used in
this document, the words "anticipate," "estimate," "expect,"
"intend," "plans," "projects," and similar expressions, as they
relate to the Company or its management, are intended to identify
forward-looking statements. Such statements reflect the current
view of the Company regarding future events and are subject to
certain risks, uncertainties and assumptions, including the risks
and uncertainties noted. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
to be incorrect, actual results may vary materially from those
described herein as anticipated, believed, estimated, expected,
intended or projected. In each instance, forward-looking
information should be considered in light of the accompanying
meaningful cautionary statements herein. Factors that could cause
results to differ include, but are not limited to, successful
performance of internal plans, the impact of competitive services
and pricing and general economic risks and uncertainties.
Contact: Taylor Capitol, Inc. Investor Relations Stephen Taylor
973-351-3868 Info@TheStockAlerts.com www.TheStockAlerts.com
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allstar Health Brands (PK) (USOTC:ALST)
Historical Stock Chart
From Jul 2023 to Jul 2024